- About
- Projects
- Research
- Advancing FDA Mechanisms to Address Complex Cross-Sectoral Health Threats
- Addressing Unmet Need Within the Animal and Veterinary Industries
- Antimicrobial Use Data in Food Animals
- Expanded Access Navigator
- Fellowship
- Food & Nutrition
- FDA Operational Evaluation
- FDA Patient Listening Sessions
- Improving Access to Publicly Available FDA Information
- Improving Understanding of the FDA and FDA-Regulated Products
- Substance Use Disorders
- COVID-19 Hub
- Regulatory Science Accelerator
- News and Events
- eRequest
Past Events
The Food and Drug Administration said Tuesday that it will launch a new research project focused on real-world evidence — data collected by insurance companies, in electronic health records, and in other places in medicine
The COVID-19 crisis has fast-tracked long-contemplated, patient-centric changes in medicine.
Amy Abernethy, FDA’s principal deputy commissioner and acting CIO, and Mark McClellan, director of the Duke-Margolis Center for Health Policy at Duke University, described in podcast interviews with BioCentury’s Washington
The U.S. has been trying to contain COVID-19 through testing and social distancing. Now it’s time to kill it.
Life won’t completely return to normal while the novel coronavirus remains a threat to health and to life.
The Reagan-Udall Foundation and Friends of Cancer Research are trying to put real-world data to use against COVID-19.
Document Drawer
"Identifying key questions and core data elements is at the heart of a new initiative launched by the Reagan-Udall Foundation and Friends of Cancer Research.
"A new initiative called the
The Reagan-Udall Foundation for the FDA (Foundation) in collaboration with Friends of Cancer Research (Friends) today announced the COVID-19 Evidence Accelerator, an expan